Canadians show rising interest in GLP-1s, but misconceptions and access barriers persist
A significant gap in understanding obesity as a chronic disease may be fuelling stigma and shaping the future of weight management benefits in Canada, according to new poll data from Phoenix, a digital health clinic for men.
Despite the rising prevalence of obesity, only 32 percent of Canadians correctly identified that Health Canada classifies obesity as a progressive chronic disease, as reported by Phoenix’s survey of over 1,500 Canadians.
This lack of awareness has tangible consequences for treatment uptake and attitudes.
Phoenix found that one in three Canadians would feel embarrassed disclosing their use of GLP-1 drugs like Ozempic or Wegovy for weight loss to friends or family.
The poll also revealed that 62 percent of Canadians believe celebrities who share their weight loss should disclose their use of weight loss drugs, with this sentiment even stronger among Gen Z respondents.
Interest in GLP-1 medications is notable, especially as Statistics Canada reports that 68 percent of Canadians are classified as overweight or obese.
However, only five percent are currently taking GLP-1 medication for weight loss, and three percent have done so in the past.
Among those who have never used a GLP-1, 21 percent would consider it in the future, with cost emerging as a potential barrier—40 percent of respondents indicated they would be interested in a generic version if struggling with obesity.
Motivations for weight loss extend beyond appearance, as improving fitness and stamina, increasing longevity, and disease prevention were cited as leading reasons by respondents.
Gavin Thompson, co-founder and co-CEO of Phoenix, states, “There is a misconception that weight loss is only an issue of vanity. That is simply not true.”
He explains that for people struggling with obesity, losing weight can significantly improve overall quality of life, including increased mobility and better sleep quality.
Eligibility for GLP-1 medications in Canada is restricted to those with a BMI of 30 or higher, or 27 or higher with obesity-related health conditions, and a prescription from a licensed physician is required.
Phoenix emphasizes that while GLP-1 drugs can play a role in weight management, lifestyle modifications such as healthy eating and regular exercise remain essential for sustainable results.
